The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

BACKGROUND: Multiple myeloma (MM) is a plasma cell tumour with an approximate annual incidence of 4500 in the UK. Therapeutic options for patients with MM have changed in the last decade with the arrival of proteasome inhibitors and immunomodulatory drugs. Despite these options, almost all patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Striha, Alina, Ashcroft, A. John, Hockaday, Anna, Cairns, David A., Boardman, Karen, Jacques, Gwen, Williams, Cathy, Snowden, John A., Garg, Mamta, Cavenagh, Jamie, Yong, Kwee, Drayson, Mark T., Owen, Roger, Cook, Mark, Cook, Gordon
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5842589/
https://ncbi.nlm.nih.gov/pubmed/29514706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-2524-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados